Market closed

Insmed/$INSM

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Ticker

$INSM
Trading on

Industry

Biotechnology

Employees

912

Insmed Metrics

BasicAdvanced
$13B
Market cap
-
P/E ratio
-$5.56
EPS
1.11
Beta
-
Dividend rate
$13B
1.11
$80.53
$21.92
1.2M
6.365
5.827
237.769
239.942
-8.45%
-26.05%
-890.75%
31.796
25.95
39.64
-17.145
22.13%
5.62%
25.44%
12.37%

What the Analysts think about Insmed

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Insmed stock.

Insmed Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Insmed Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INSM

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Insmed stock?

Insmed (INSM) has a market cap of $13B as of November 13, 2024.

What is the P/E ratio for Insmed stock?

The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of November 13, 2024.

Does Insmed stock pay dividends?

No, Insmed (INSM) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next Insmed dividend payment date?

Insmed (INSM) stock does not pay dividends to its shareholders.

What is the beta indicator for Insmed?

Insmed (INSM) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.